BLA 761112 · Ablynx Nv
Cablivi
Caplacizumab-Yhdp · Injection
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Dec 23, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Feb 6, 2019
Approved uses
2
Original approval plus efficacy supplements
Registered trials
9
4 Phase 3, 0 recruiting
FAERS reports
1,784
749 serious, 109 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 24, 2026.
CABLIVI is indicated for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy. CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult and pediatric patients 12 years of age and older with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy. ( 1 )
Mechanism: Caplacizumab-yhdp targets the A1-domain of vWF, and inhibits the interaction between vWF and platelets, thereby reducing both vWF-mediated platelet adhesion and platelet consumption.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 23, 2025 Supplement 18 · Efficacy · priority review OrphanLabelLetter
- Feb 6, 2019 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- CABLIVI · CAPLACIZUMAB-YHDP 11MG/VIAL · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Caplacizumab" as an intervention, any sponsor and status, largest first.
- Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) PatientsPivotal-lookingCompleted
Ablynx, a Sanofi companyIndustry
NCT01020383 · 364 participants · Start Sep 2009 · Primary completion Apr 2011
Drug: ALX-0081; ReoPro® · For: Unstable Angina; Non ST Segment Elevation Myocardial Infarction (NSTEMI); Stable Angina (Associated With High Risk PCI)
Sites: Graz, Austria; Linz, Austria; Vienna, Austria · 39 sites in all
- Phase III Trial With Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic PurpuraPivotal-lookingCompleted
Ablynx, a Sanofi companyIndustry
NCT02553317 · 145 participants · Start Nov 2015 · Primary completion Aug 2017
Drug: Caplacizumab; Placebo · For: Acquired Thrombotic Thrombocytopenic Purpura
Sites: Birmingham, Alabama; Los Angeles, California; Atlanta, Georgia · 101 sites in all
- Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)Pivotal-lookingCompleted
SanofiSanofi (SNY)
NCT02878603 · 104 participants · Start Oct 6, 2016 · Primary completion Oct 23, 2020
Drug: Caplacizumab · For: Acquired Thrombotic Thrombocytopenic Purpura
Sites: St Louis, Missouri; Valhalla, New York; Durham, North Carolina · 45 sites in all
Ablynx, a Sanofi companyIndustry
NCT01151423 · 75 participants · Start Jan 2011 · Primary completion Mar 2014
Drug: Caplacizumab; Placebo · For: Acquired Thrombotic Thrombocytopenic Purpura
Sites: Los Angeles, California; Washington D.C., District of Columbia; Atlanta, Georgia · 51 sites in all
Ablynx, a Sanofi companyIndustry
NCT03172208 · 60 participants · Start Jun 5, 2017 · Primary completion Oct 19, 2017
Drug: Caplacizumab Dose 1 iv (single-dose); Caplacizumab Dose 2 iv (single-dose) and 2 more · For: Healthy Volunteers
Sites: Glendale, California
- Efficacy of a Personalized Caplacizumab Regimen Based on ADAMTS13 Activity Monitoring in Adult aTTPTerminated
University Hospital, RouenAcademic, hospital or other
NCT04720261 · 58 participants · Start Apr 26, 2021 · Primary completion May 16, 2023
Drug: Caplacizumab · For: Thrombotic Thrombocytopenic Purpura, Acquired
Sites: Amiens, France; Angers, France; Besançon, France · 24 sites in all
- Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic PurpuraPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT05468320 · 51 participants · Start Nov 21, 2022 · Primary completion Dec 26, 2024
Drug: Caplacizumab; Corticosteroids and 1 more · For: Thrombotic Thrombocytopenic Purpura
Sites: Birmingham, Alabama; Baltimore, Maryland; Durham, North Carolina · 27 sites in all
- Bioequivalence of Liquid and Reconstituted Lyophilized Subcutaneous Formulations of Caplacizumab.Completed
Ablynx, a Sanofi companyIndustry
NCT02189733 · 24 participants · Start Jul 2014 · Primary completion Sep 2014
Drug: Caplacizumab · For: Healthy Volunteers
Sites: Nottingham, United Kingdom
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- product use in unapproved indication619
- off label use208
- adamts13 activity decreased161
- epistaxis133
- platelet count decreased133
- fatigue111
- contusion89
- thrombotic thrombocytopenic purpura84
- headache83
- injection site pain82
- condition aggravated80
- adamts13 activity abnormal73
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2019 | 132 |
| 2020 | 194 |
| 2021 | 240 |
| 2022 | 269 |
| 2023 | 256 |
| 2024 | 236 |
| 2025 | 270 |
| 2026 | 187 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Cablivi (Caplacizumab-Yhdp)
2024 spending
$24.6M
Beneficiaries
50
113 claims
Per beneficiary
$491,222
$8,151.71 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $13,383,596 |
| 2021 | $12,714,119 |
| 2022 | $17,437,325 |
| 2023 | $20,162,189 |
| 2024 | $24,561,101 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.
Scully M, Cataland SR, Peyvandi F, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura.
Peyvandi F, Scully M, Kremer Hovinga JA, et al. · N Engl J Med 2016 · Clinical Trial, Phase II, Multicenter Study
- Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
Djulbegovic M, Tong J, Xu A, et al. · Blood Adv 2023 · Meta-Analysis, Systematic Review
- Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
He J, Qi J, Han H, et al. · Expert Rev Hematol 2023 · Meta-Analysis, Systematic Review
- Efficacy and relative safety of caplacizumab in immune-mediated thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.
Peng JY, Wang SY, Chen MQ, et al. · Blood Coagul Fibrinolysis 2024 · Systematic Review, Meta-Analysis
- The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study.
Miyakawa Y, Imada K, Ichikawa S, et al. · Int J Hematol 2023 · Clinical Trial, Phase III, Clinical Trial, Phase II
Sponsor: Ablynx Nv
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.